New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
10:55 EDTBNNY, USG, DYN, BDSI, IDIX, SLXP, CCIH, ACHN, VIP, NKTRHigh option volume stocks:
High option volume stocks: BNNY VIP ACHN CCIH SLXP IDIX BDSI DYN USG NKTR
News For BNNY;VIP;ACHN;CCIH;SLXP;IDIX;BDSI;DYN;USG;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 23, 2014
08:31 EDTSLXPSalix takeout price could be $200 per share, says Leerink
Leerink estimates a takeout valuation for Salix (SLXP) of $200 per share, but says it would start recommending investors take profits above $185. The firm believes a potential deal with Allergan (AGN) would likely include an above-average break-up fee. Leerink thinks a competitive bid could surface, and points out Actavis (ACT) has more overlapping cost structure with Salix than Allergan. Shares of Salix are up 9% to $173.48 in pre-market trading after Wall Street Journal reported the company is in merger talks with Allergan.
08:15 EDTDYNDynegy resumed with a Buy at Deutsche Bank
Subscribe for More Information
07:52 EDTCCIHDaiwa Securities Group to hold a conference
Subscribe for More Information
07:07 EDTSLXPSalix price target raised to $181 from $154 at Cantor
Subscribe for More Information
06:28 EDTSLXPTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
September 22, 2014
19:08 EDTSLXPSalix up nearly 10% after hours following WSJ report of possible takeover
Subscribe for More Information
19:03 EDTSLXPAllergan rejected buyout bid from Actavis, in advanced talks for Salix, WSJ says
Subscribe for More Information
09:08 EDTBNNYGeneral Mills commences tender offer for Annie's for $46 per share
General Mills (GIS) announced that its direct wholly owned subsidiary, Sandy Acquisition Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Annie's (BNNY) at a price of $46.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated as of September 8, 2014, by and among General Mills, Sandy Acquisition Corporation and Annie's, Inc., which General Mills and Annie's announced on September 8, 2014. The board of Annie's has unanimously determined that the offer is fair and advisable and in the best interests of Annie's and its stockholders, and recommends that the stockholders of Annie's accept the offer and tender their shares. The tender offer is scheduled to expire at the end of the day on October 20, 2014, unless extended.
08:09 EDTSLXPPar Pharmaceutical in settlement deal with Salix
Subscribe for More Information
September 19, 2014
09:01 EDTNKTRNektar presents preclinical data on kappa opioid receptor
Nektar announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral, peripherally-acting kappa opioid receptor agonist molecules. The analgesic properties of kappa receptor agonism are well described in the medical literature.1,2 Kappa opioid receptors are expressed in the peripheral nervous system as well as in the central nervous system, and activation of these receptors at both sites has been shown to result in a reduction in pain and inflammation in a wide range of preclinical models. However, the therapeutic use of kappa receptor agonists has been limited because activation of these receptors in the CNS is associated with significant dysphoria and other unwanted side effects.
07:54 EDTSLXPSalix price target raised to $192 from $161 at Canaccord
Subscribe for More Information
September 18, 2014
13:44 EDTSLXPSalix announces FDA sNDA resubmission for XIFAXAN complete
Subscribe for More Information
07:31 EDTSLXPSalix secures additional intellectual property relating to Rifaximin
Salix Pharmaceuticals announced that Cipla granted Salix exclusive rights under certain patent applications in the “Rifaximin Complexes” patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the U.S., Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the U.S., Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the “Rifaximin Complexes” patent rights. Salix also will pay royalties on net sales of products covered by the “Rifaximin Complexes” patents licensed to Salix
September 17, 2014
11:11 EDTBNNYGeneral Mills crumbles after earnings miss, downgrade
Subscribe for More Information
10:54 EDTDYNDynegy sees 2015 adjusted EBITDA $1.2B-$1.4B
Subscribe for More Information
08:50 EDTNKTRNektar Movantik approval positive, says Roth Capital
Subscribe for More Information
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.
08:30 EDTBNNYGeneral Mills sees Annie's deal closing in CY14
General Mills (GIS) says sees Annie's (BNNY) deal accretive in first 12 months after closing. Says on pace to achieve $4B of cumulative savings from 2010-2020. Sees $400M of cumulative savings in FY15. Says top priority for FY15 is accelerating net sales growth. Comments from slides that will be presented on the Q1 earnings conference call.
08:02 EDTSLXPSalix M&A chatter warranted, says Canaccord
Subscribe for More Information
07:36 EDTDYNWolfe Research to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use